Drug Delivery Strategies for the Lower GI Tract: A Review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40916179.
- Also identified by DOI 10.1002/adhm.202501540.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The lower gastrointestinal (GI) tract is affected by a range of diseases, including colorectal cancer and inflammatory bowel disease, among others. Effective treatment of these conditions requires drug delivery systems (DDSs) capable of precise targeting. While pH- and enzyme-sensitive DDSs are the most used, they often suffer from premature drug release and target specificity, limiting their efficacy. To address this challenge, researchers are exploring alternative triggers, such as reactive oxygen species (ROS), reduction-oxidation (redox) and modified enzyme- and pH-responsive systems, to enhance specificity and performance. This review highlights the latest advancements and current limitations in targeted drug delivery strategies for the lower GI tract, aiming to improve therapeutic outcomes and the quality of life for patients with intestinal disorders.
Medical subject headings
- Drug Delivery Systems
- Gastrointestinal Tract